Genmab A/S Stock Price, News & Analysis
Company Description
Genmab A/S (GNMSF) is a foreign private issuer whose securities are associated with the ticker GNMSF. According to its regulatory disclosures, Genmab A/S files reports with the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934 as a non‑U.S. company. The company uses Form 6-K to furnish current reports and references multiple registration statements on Form S-8, indicating that it has registered securities for employee or related compensation plans.
In an SEC filing identified as a Form 6-K for the month of September 2025, Genmab A/S states that the report is furnished pursuant to Rule 13a-16 or 15d-16 of the Exchange Act. The filing also specifies that the Form 6-K is deemed to be incorporated by reference into several of the company’s existing Form S-8 registration statements. This linkage shows how Genmab A/S integrates its ongoing current reports into its broader U.S. securities registration framework.
Genmab A/S is based in Denmark, with its address in Valby, Denmark, as disclosed in the Form 6-K. The filing further notes that the company files annual reports under cover of Form 20-F or Form 40-F, and includes a check-box section for this purpose. This confirms that Genmab A/S follows the foreign issuer reporting regime rather than the domestic U.S. issuer framework.
The September 2025 Form 6-K includes an exhibit index listing a Company Announcement: Major Shareholder Announcement and a Standard form for notification of major holdings. This indicates that Genmab A/S provides market updates related to significant shareholdings and uses standardized notification formats for major holdings, which can be relevant for investors monitoring changes in substantial ownership positions.
Because the available information is drawn from a specific SEC filing, detailed information about the company’s industry, sector, products, or services is not provided here. Investors researching GNMSF can use this overview as a starting point to understand that Genmab A/S is a Denmark-based foreign issuer with securities registered in the United States and that it communicates major shareholder information through Form 6-K exhibits.
Stock Performance
Genmab A/S (GNMSF) stock last traded at $265.00. Over the past 12 months, the stock has gained 39.6%. At a market capitalization of $16.3B, GNMSF is classified as a large-cap stock with approximately 61.6M shares outstanding.
Latest News
SEC Filings
Genmab A/S has filed 5 recent SEC filings, including 5 Form 6-K. The most recent filing was submitted on April 1, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all GNMSF SEC filings →
Financial Highlights
Genmab A/S generated $3.7B in revenue over the trailing twelve months, and net income was $963.0M, reflecting a 25.9% net profit margin. The company generated $1.2B in operating cash flow. With a current ratio of 2.02, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Genmab A/S (GNMSF) currently stands at 114.9 thousand shares, down 20.9% from the previous reporting period, representing 0.2% of the float. Over the past 12 months, short interest has increased by 57.4%. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Genmab A/S (GNMSF) currently stands at 1000.0 days. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 22888.3% over the past year, indicating improving liquidity conditions. The ratio has shown significant volatility over the period, ranging from 3.4 to 1000.0 days.
GNMSF Company Profile & Sector Positioning
Genmab A/S (GNMSF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.